Adverse myocardial effects of B-vitamin therapy in subjects with chronic kidney disease and hyperhomocysteinaemia.
OBJECTIVE
Hyperhomocysteinaemia (HHCY), a common finding in patients with chronic kidney disease (CKD), has been shown to contribute to adverse cardiac remodelling and failure. We hypothesised that in human subjects with CKD, HHCY would be associated with myocardial dysfunction, and that homocysteine (HCY)-lowering therapy would improve myocardial remodelling and heart-failure (HF) outcomes.


RESULTS
Post hoc analysis of the Homocysteinemia in Kidney and End Stage Renal Disease (HOST) trial (n=2056) was performed to determine if HCY-lowering therapy with high dose B vitamins affects HF outcomes in patients with CKD. In addition, effects on myocardial remodelling were assessed in a subgroup of 220 trial subjects who had transthoracic echocardiograms done before study randomisation and during the course of the study as part of their routine clinical care. HF outcomes were not significantly affected by treatment compared to the placebo. HCY levels were inversely correlated with diastolic function (R=-0.21; p=0.038). Vitamin therapy resulted in a significant increase in left atrial size (+0.15±0.8 cm vs. -0.13±0.07 cm; p=0.0095). No other echocardiographic parameters were significantly associated with baseline HCY levels or changes with vitamin therapy.


CONCLUSIONS
HHCY is associated with diastolic dysfunction in patients with CKD. However, B-vitamin therapy did not improve HF outcomes despite lowering of plasma HCY levels, and was associated with an increase in left atrial size, which is a surrogate for worsening left ventricular diastolic dysfunction. These findings suggest that high-dose B vitamin therapy may be harmful in patients with CKD.
Veteran Affairs Boston Healthcare System, Department of Medicine, Boston, MA, USA.
Z
Z
Rafeq
J D
JD
Roh
P
P
Guarino
J
J
Kaufman
J
J
Joseph
D000368:Aged; D015992:Body Mass Index; D015331:Cohort Studies; D005500:Follow-Up Studies; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006333:Heart Failure / Q000209:etiology / Q000503:physiopathology*; D006710:Homocysteine / Q000097:blood; D006801:Humans; D020138:Hyperhomocysteinemia / Q000188:drug therapy*; D008875:Middle Aged; D011446:Prospective Studies; D012044:Regression Analysis; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy*; D012709:Serum Albumin / Q000378:metabolism; D014803:Vitamin B Complex / Q000008:administration & dosage* / Q000009:adverse effects*; D014815:Vitamins / Q000008:administration & dosage / Q000009:adverse effects
D012709:Serum Albumin; D014815:Vitamins; D006710:Homocysteine; D014803:Vitamin B Complex